San Diego, CA, May 25, 2010: KFx Medical Corporation announced today it has received FDA 510k clearance for product(s) used in a wide variety of arthroscopic tenodesis knee procedures such as: anterior cruciate ligament (ACL), posterior cruciate ligament (PCL), and Medial Patellofemoral Ligament (MPFL) reconstruction.
KFx Medical received 510k clearance from the Food and Drug Administration for its AppianFx™ product line for soft tissue repair and reconstruction in the knee. “The AppianFx for knee ligament/tissue fixation continues our focus on providing products, with broad intellectual protection, that enable surgeons to more quickly and easily perform complex procedures. This clearance to market our AppianFx family of implants significantly expands the number of surgical procedures for which we provide products to now include all extremities,” indicated Tate Scott, president and CEO of KFx Medical.
The AppianFx line of implants from KFx reattach tissue to bone in shoulder, knee, foot and ankle procedures which combined exceed well over 1 million annual surgical procedures. Product offerings include those that directly place and secure tissue into bone both with and without the use of sutures.
About KFx Medical Corporation
Headquartered in Carlsbad, Calif., KFx Medical Corporation was founded in 2003 to develop products for tissue fixation in a variety of orthopedic surgical procedures performed on the shoulder, knee, foot, and ankle. KFx provides simple systems for orthopedic surgeons focused on sports medicine. The company is privately held — Investors include Alloy Ventures (www.alloyventures.com), Charter Life Sciences (www.charterls.com), Arboretum Ventures (www.arboretumvc.com), Montreux Equity Partners (www.montreuxequity.com/sec), and MB Venture Partners (www.mbventures.com).
For more information, please contact Tate Scott – Tate.Scott@kfxmed.com